Chong Kun Dang Pharmaceutical

종근당 · 185750

Health Care Pharmaceuticals · KOSPI

Small-cap

Market cap US$766.2M (₩1.1T)

Overview

Chong Kun Dang Pharmaceutical makes prescription and over-the-counter medicines supplied to patients and healthcare providers in Korea.

It is listed on KOSPI, Korea's main stock exchange. The filing's structural sections cover a broad pharmaceutical business spanning product development, manufacturing, and research and development activities, though the filing text does not detail a single dominant product line.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025

Revenue · FY2025

US$1.2B

▲ +6.7% YoY

Operating profit · FY2025

US$58.4M

▼ −19.0% YoY

Net income · FY2025

US$56.4M

▼ −30.2% YoY

Revenue, operating profit and net income by fiscal year (USD; KRW in parentheses).
Metric	FY2023	FY2024	FY2025
Revenue	US$1.2B(₩1.7T)	US$1.1B(₩1.6T)	US$1.2B(₩1.7T)
Operating profit	US$178.7M(₩246.6B)	US$72.1M(₩99.5B)	US$58.4M(₩80.6B)
Net income	US$154.8M(₩213.6B)	US$80.8M(₩111.4B)	US$56.4M(₩77.8B)

Revenue

FY2023US$1.2B
FY2024US$1.1B
FY2025US$1.2B

Operating profit

FY2023US$178.7M
FY2024US$72.1M
FY2025US$58.4M

Net income

FY2023US$154.8M
FY2024US$80.8M
FY2025US$56.4M

Key ratios (FY2025)

ROE

7.7%

Debt/Eq

78.9%

Op. margin

4.8%

Net margin

4.6%

Rev. YoY

▲ +6.7%

Price charts coming soon

Interactive price history isn't here yet. Would you use it?